Sector News

J&J Q4 sales up 1.7 pct, plans to divest diabetes care division

January 25, 2017
Life sciences

Johnson & Johnson reported a 1.7 percent rise in fourth-quarter sales, due to a strong demand for its newer products.

The diversified healthcare company’s sales rose to $18.11 billion in the fourth quarter from $17.81 billion a year earlier.

Net earnings rose to $3.81 billion, or $1.38 per share, from $3.22 billion, or $1.15 per share.

The band-aid maker also said on Tuesday that it was looking to divest its diabetes care division.

By Natalie Grover

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.